NODAGA-LM3 (TFA)

• UNSPSC Description:

  NODAGA-LM3 TFA can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas[1][2].

• Target Antigen:

  Radionuclide-Drug Conjugates (RDCs); Somatostatin Receptor

• Type:

  Peptides

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;GPCR/G Protein;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/nodaga-lm3-tfa.html

• Purity:

  96.35

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H]1CC2=CC=C(NC(N)=O)C=C2)[C@H](CC3=CC=C(O)C=C3)NC([C@H](NC([C@H](CC4=CC=C(Cl)C=C4)NC(CCC(C(O)=O)N5CCN(CC(O)=O)CCN(CC(O)=O)CC5)=O)=O)CSSC[C@@H](C(N[C@H](CC6=CC=C(O)C=C6)C(N)=O)=O)NC([C@]([H])([C@@H](C)O)NC([C@H](CCCCN)NC1=O)=O)=O)=O.O=C(C(F)(F)F)O.[x]

• Molecular Weight:

  1521.11 (free acid)

• References & Citations:

  [1]Fani M, et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011 Jul;52(7):1110-8. |[2]Zhu W, et al. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors. J Nucl Med. 2021 Oct;62(10):1398-1405.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Phase 2